CR4056, a new analgesic I2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats

Journal of Pain Research

Volumn 5, Issue , 2012, Pages 151-167

  Meregalli, Cristina ^a   Ceresa, Cecilia ^a   Canta, Annalisa ^a   Carozzi, Valentina Alda ^a   Chiorazzi, Alessia ^a   Sala, Barbara ^a   Oggioni, Norberto ^a   Lanza, Marco ^b   Letari, Ornella ^b   Ferrari, Flora ^b   Avezza, Federica ^a   Marmiroli, Paola ^a   Caselli, GianFranco ^b   Cavaletti, Guido ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Rotta Research Laboratorium   (Italy)

Author keywords

Allodynia; Antinociception; Bortezomib; Imidazoline I2 receptor ligand; Neuropathic pain

Indexed keywords

ANALGESIC AGENT; BORTEZOMIB; BUPRENORPHINE; CR 4056; GABAPENTIN; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; NERVE CONDUCTION; NEUROPATHIC PAIN; NEUROPATHY; NEUROPHYSIOLOGY; NONHUMAN; PAIN ASSESSMENT; PAIN THRESHOLD; RAT; SCIATIC NERVE;

EID: 84874958619     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S32122     Document Type: Article

References (54)

1. Kannarkat G, Lasher EE, Schiff D. Neurologic complications of chemotherapy agents. Curr Opin Neurol. 2007;20(6):719-725.
2. Kuroi K, Shimozuma K. Neurotoxicity of taxanes: symptoms and quality of life assessment. Breast Cancer. 2004;11(1):92-99.
3. Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst. 2008;13(1):27-46.
4. Cata JP, Weng HR, Lee BN, Reuben JM, Dougherty PM. Clinical and experimental finding in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol. 2006;72(3):151-169.
5. Bennett GJ. Neuropathic pain. In: Wall PD, Melzack R, editors. Textbook of Pain. 3rd ed. London: Churchill Livingston; 1994:201-220.
6. Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron. 2006;52(1):77-92.
7. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59(11):2615-2622.
8. Curran MP, McKeage K. Bortezomib: a review of its use in patients with multiple myeloma. Drugs. 2009;69(7):859-888.
9. Tobinai K. Proteasome inhibitor, bortezomib, for myeloma and lymphoma. Int J Clin Oncol. 2007;12(5):318-326.
10. Kennedy B, Gargoum F, Bystricky B, Curran DR, O'Connor TM. Novel agents in the management of lung cancer. Curr Med Chem. 2010;17(35): 4291-4325.
11. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277(19): 16639-16647.
12. Lenz HJ. Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev. 2003;29 Suppl 1:S41-S48.
13. Cavaletti G, Nobile-Orazio E. Bortezomib-induced peripheral neurotoxicity: still far from a painless gain. Haematologica. 2007; 92(10):1308-1310.
14. Parini A, Moudanos CG, Pizzinat N, Lanier SM. The elusive family of imidazoline binding sites. Trends Pharmacol Sci. 1996;17(1):13-16.
15. Finn DP, Martí O, Harbuz MS, et al. Behavioral, neuroendocrine and neurochemical effects of the imidazoline I2 receptor selective ligand BU224in naive rats and rats exposed to the stress of the forced swim test. Psychopharmacology (Berl). 2003;167(2):195-202.
16. Head GA, Mayorov DN. Imidazoline receptors, novel agents and therapeutic potential. Cardiovasc Hematol Agents Med Chem. 2006; 4(1):17-32.
17. Lione LA, Nutt DJ, Hudson AL. Characterisation and localisation of [3H]2-(2-benzofuranyl)-2-imidazoline binding in rat brain: a selective ligand for imidazoline I2 receptors. Eur J Pharmacol. 1998;353(1):123-135.
18. Li JX, Zhang Y. Imidazoline I2 receptors: target for new analgesics? Eur J Pharmacol. 2011;658(2-3):49-56.
19. Eglen RM, Hudson AL, Kendall DA, et al. 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. Trends Pharmacol Sci. 1998;19(9):381-390.
20. Mattia C, Coluzzi F. Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain. IDrugs. 2007;10(9):636-644.
21. Dina OA, Khasar SG, Alessandri-Haber N, et al. Neurotoxic catecholamine metabolite in nociceptors contributes to painful peripheral neuropathy. Eur J Neurosci. 2009;28(6):1180-1190; partial retraction in Eur J Neurosci. 2009;30(11):2235.
22. Ferrari F, Fiorentino S, Mennuni L, et al. Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain. J Pain Res. 2011;4:111-125.
23. Hwang SL, Liu IM, Tzeng TF, Cheng JT. Activation of imidazoline receptors in adrenal gland to lower plasma glucose in streptozotocin-induced diabetic rats. Diabetologia. 2005;48(4):767-775.
24. Chang CH, Wu HT, Cheng KC, Lin HJ, Cheng JT. Increase of beta-endorphin secretion by agmatine is induced by activation of imidazoline I(2A) receptors in adrenal gland of rats. Neurosci Lett. 2010;468(3):297-299.
25. Cavaletti G, Gilardini A, Canta A, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol. 2007;204(1):317-325.
26. Canta A, Chiorazzi A, Meregalli C, et al. Continuous buprenorphine delivery effect in streptozotocine-induced painful diabetic neuropathy in rats. J Pain. 2009;10(9):961-968.
27. Meregalli C, Canta A, Carozzi VA, et al. Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur J Pain. 2010;14(4):343-350.
28. Canta A, Chiorazzi A, Carozzi V, et al. In vivo comparative study of the cytotoxicity of a liposomal formulation of cisplatin (Lipoplatin™). Cancer Chemother Pharmacol. 2011;68(4):1001-1008.
29. Cavaletti G, Cavalletti E, Montaguti P, Oggioni N, De Negri O, Tredici G. Effect on the peripheral nervous system of the short-term intravenous administration of paclitaxel in the rat. Neurotoxicology. 1997;18(1):137-145.
30. Cavaletti G, Fabbrica D, Minoia C, Frattola L, Tredici G. Carboplatin toxic effects on the peripheral nervous system of the rat. Ann Oncol. 1998;9(4):443-447.
31. Motta EM, Calixto JB, Rae GA. Mechanical hyperalgesia induced by endothelin-1in rats is mediated via phospholipase C, protein kinase C, and MAP kinases. Exp Biol Med (Maywood). 2006;231(6): 1141-1145.
32. Cavaletti G, Tredici G, Marmiroli P, Petruccioli MG, Barajon I, Fabbrica D. Morphometric study of the sensory neuron and peripheral nerve changes induced by chronic cisplatin (DDP) administration in rats. Acta Neuropathol. 1992;84(4):364-371.
33. Persohn E, Canta A, Schoepfer S, et al. Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats. Eur J Cancer. 2005;41(10):1460-1466.
34. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431-440.
35. Kortüm M, Einsele H. Results of the first bortezomib-based induction therapy in the treatment of multiple myeloma. Expert Opin Pharmacother. 2011;12(10):1661-1663.
36. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008;112(5):1593-1599.
37. Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL, Mohty M. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica. 2010;95(2):311-319.
38. Obata H, Saito S, Koizuka S, Nishikawa K, Goto F. The monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain. Anesth Analg. 2005;100(5):1406-1410.
39. Sawynok J, Esser MJ, Reid AR. Peripheral antinociceptive actions of desipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat. Pain. 1999;82(2):149-158.
40. McQuay HJ, Tramèr M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain. 1996;68(2-3):217-227.
41. Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain: consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag. 2007;12(1):13-21.
42. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain: a Cochrane review. J Neurol Neurosurg Psychiatry. 2010;81(12):1372-1373.
43. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012;82(1):51-77.
44. Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma. 2010;51(7):1178-1187.
45. Bruna J, Udina E, Alé A, et al. Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Exp Neurol. 2010;223(2):599-608.
46. Ruiz-Durántez E, Torrecilla M, Pineda J, Ugedo L. Attenuation of acute and chronic effects of morphine by the imidazoline receptor ligand 2-(2-benzofuranyl)-2-imidazoline in rat locus coeruleus neurons. Br J Pharmacol. 2003;138(3):494-500.
47. Raddatz R, Parini A, Lanier SM. Imidazoline/guanidinium binding domains on monoamine oxidases. Relationship to subtypes of imidazoline-binding proteins and tissue-specific interaction of imidazoline ligands with monoamine oxidase B. J Biol Chem. 1995; 270(46):27961-27968.
48. Vega JA, Amenta F, Hernandez LC, del Valle ME. Presence of catecholamine-related enzymes in a subpopulation of primary sensory neurons in dorsal root ganglia of the rat. Cell Mol Biol. 1991;37(5):519-530.
49. Jasmin L, Tien D, Janni G, Ohara PT. Is noradrenaline a significant factor in the analgesic effect of antidepressants? Pain. 2003;106(1-2):3-8.
50. Bannister K, Bee LA, Dickenson AH. Preclinical and early clinical investigations related to monoaminergic pain modulation. Neurotherapeutics. 2009;6(4):703-712.
51. Thorn DA, An XF, Zhang Y, Pigini M, Li JX. Characterization of the hypothermic effects of imidazoline I(2) receptor agonists in rats. Br J Pharmacol. Epub February 10, 2012.
52. Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci. 2007;10(11):1361-1368.
53. Kusunose N, Koyanagi S, Hamamura K, et al. Molecular basis for the dosing time-dependency of anti-allodynic effects of gabapentin in a mouse model of neuropathic pain. Mol Pain. 2010;6:83.
54. Flatters SJ. Effect of analgesic standards on persistent postoperative pain evoked by skin/muscle incision and retraction (SMIR). Neurosci Lett. 2010;477(1):43-47.